Boyd Technologies announced today the appointment of Charles L. Cooney to its Board of Directors, effective February 20, 2014. The Board, which consists of three independent directors and three managing executives, is tasked with increasing shareholder value consistent with the Company’s strategic growth plan.
“We are pleased to announce the appointment of Dr. Cooney to our Board of Directors. Dr. Cooney brings with him a tremendous expertise in biopharmaceutical manufacturing and engineering accompanied by an acute business acumen and experience with technological innovation and new venture creation,” said, Bronly Boyd the Chairman of the Board.
Commenting on the appointment, the Company’s CEO, Stephen Boyd, said “It is an exciting time for our business. We launched an aggressive five year growth plan in 2013 and we are supporting that with significant investments in our technologies, people, and knowledge base. We are thrilled to have the guidance and insight Dr. Cooney brings to our core medical and biopharmaceutical markets.”
About Charles L. Cooney
Charles L. Cooney is the Robert T. Haslam (1911) Professor of Chemical and Biochemical Engineering in the MIT Department of Chemical Engineering and the founding Faculty Director of the Deshpande Center for Technological Innovation which was established to foster innovation and spurring new-company formation from MIT research, and plays a key role in the grant selection process. As faculty director of the Deshpande Center, he is interested in the process of stimulating technological innovation and translating innovation into the creation of new ventures.
Professor Cooney's research and teaching activities, which span a range of topics in biochemical engineering and pharmaceutical manufacturing which include manufacturing in the pharmaceutical, biotech and biofuels industries; bioprocess design, operation and control; and processing of pharmaceutical powders.
Among his many honors, Professor Cooney has received the 1989 Gold Medal of the Institute of Biotechnological Studies (London); the Food, Pharmaceutical and Bioengineering Award from the American Institute of Chemical Engineers; and the James Van Lanen Distinguished Service Award from the American Chemical Society's Division of Microbial and Biochemical Technology. He was elected to the American Institute of Medical and Biochemical Engineers and in 2009 was elected to the first class of American Chemical Society Fellows. In July 2012 he was awarded Honoris Causa by Ramon Llull University in Barcelona.
Professor Cooney serves as a consultant to a number of biotech and pharmaceutical companies, is on the editorial boards of multiple professional journals, sits on the Boards of Directors of Polypore International, Inc., Mitra (India), GreenLight Bioscience, Pronutria, Inc. and Biocon, Ltd (India) and was previously on the Boards of Genzyme, Cuno, Inc., Pall Corp. and Astra AB. He chaired the FDA Advisory Committee for Pharmaceutical Science from 2004-2006.
He received his Bachelor's degree in Chemical Engineering from the University of Pennsylvania (1966) and his Master's (1967) and Ph.D. (1970) degrees in Biochemical Engineering from MIT. After a short post-doctoral time at the Squibb Institute for Medical Research, he joined the MIT faculty in 1970 as an Assistant Professor and became a full Professor in 1982. Professor Cooney is a Trustee Emeriti of Boston Ballet, and an Overseer of the Boston Symphony Orchestra.
About Boyd Technologies
Boyd Technologies is a leading international supplier of advanced flexible materials. Global OEM partners rely on Boyd Technologies for material sourcing, product realization, and precision converting. Together these capabilities provide design and development, commercialization support, and production of products which are made from advanced flexible materials. The Company is ISO 9001 and 13485 certified.
The Company works with nonwovens, membranes, films, foils, foam, technical papers, extruded netting, technical textiles, hydrocolloid, hydrogel, alginate, and composite materials. These flexible materials are used in technical applications across the medical, electrical, and consumer markets. The Company’s core technologies and developments are in biopharmaceutical filtration, advanced wound care, and power storage and delivery products and applications.
Boyd Technologies is privately held and controlled by the Boyd Family. The Company is overseen by its Board of Directors which is comprised of independent and executive directors, and lead by its Senior Management team which is responsible for the successful execution of the Company's strategic growth plan. Boyd Technologies is headquartered in South Lee, Massachusetts and operates globally with its network of customers and partners.